论文部分内容阅读
目的:观察不同浓度雌激素对SKBR-3乳腺癌细胞血管内皮生长因子(vascular endothelial growth factor,VEGF)表达的影响,并探讨不同浓度雌激素作用条件下,贝伐单抗(VEGF单抗)、曲妥珠单抗(HER-2单抗)、紫杉醇和胰岛素样生长因子1受体(insulin-like growth factor receptor,IGF-1R)抗体对SKBR-3乳腺癌细胞VEGF表达的影响。方法:利用RT-PCR方法检测SKBR-3乳腺癌细胞在不同浓度雌激素以及VEGF单抗(0.5μg/mL)、HER-2单抗(0.04μg/mL)、紫杉醇(1.5μg/mL)和IGF-1R抗体(2.5μg/mL)作用下,SKBR-3乳腺癌细胞VEGF的表达状况,利用ELISA方法检测培养液上清中VEGF蛋白浓度。结果:1)无雌激素组SKBR-3乳腺癌细胞VEGF表达为1.061 8±0.008 5(VEGF/GAPDH,下同),低浓度雌激素(0.05μg/mL)组为1.004 7±0.006 1,差异有统计学意义,P=0.002,高浓度雌激素(0.2μg/mL)组为1.086 8±0.013 5,差异有统计学意义,P<0.001。2)用与不用紫杉醇SKBR-3乳腺癌细胞VEGF表达分别为1.049 6±0.028 8和1.061 8±0.008 5,F=0.058;用与不用IGF-1R单抗为1.088 4±0.003 6和1.061 8±0.008 5,F=0.073;用与不用HER-2单抗分别为0.988 7±0.003 7和1.061 8±0.008 5,F=0.075;同时,在应用紫杉醇、IGF-1R单抗、HER-2单抗基础上加用雌激素VEGF表达不受影响。3)用与不用VEGF单抗SKBR-3乳腺癌细胞VEGF表达分别为1.005 7±0.004 3、1.061 8±0.008 5,差异有统计学意义,F=0.132,P=0.04;但雌激素与VEGF单抗对VEGF表达影响没有协同作用。结论:不同雌激素浓度对SKBR-3乳腺癌细胞VEGF表达影响明显;紫杉醇、IGF-1R单抗和HER-2单抗不影响SKBR-3乳腺癌细胞VEGF表达,与雌激素也无协同作用;VEGF单抗升高VEGF表达,也与雌激素没有协同作用。
OBJECTIVE: To observe the effect of different concentrations of estrogen on the expression of vascular endothelial growth factor (VEGF) in SKBR-3 breast cancer cells and to investigate the effect of different concentrations of estrogen on the expression of VEGF monoclonal antibody Effects of trastuzumab (HER-2 mAb), paclitaxel and insulin-like growth factor receptor (IGF-1R) on VEGF expression in SKBR-3 breast cancer cells. Methods: The proliferation of SKBR-3 breast cancer cells in different concentrations of estrogen and VEGF monoclonal antibody (0.5μg / mL), HER-2 mAb (0.04μg / mL), paclitaxel The expression of VEGF in SKBR-3 breast cancer cells treated with IGF-1R antibody (2.5μg / mL), and the concentration of VEGF protein in the culture supernatant were detected by ELISA. Results: 1) The expression of VEGF in SKBR-3 breast cancer cells without estrogen was 1.061 8 ± 0.008 5 (VEGF / GAPDH, the same below) and 1.004 7 ± 0.006 1 in low estrogen (0.05μg / mL) (P = 0.002, P <0.001.2) with high estrogen (0.2μg / mL) group was 1.086 8 ± 0.013 5, the difference was statistically significant, P <0.001.2) with and without taxol SKBR-3 breast cancer cells VEGF Expression was 1.049 6 ± 0.028 8 and 1.061 8 ± 0.008 5, respectively, F = 0.058; with and without IGF-1R mAb 1.088 4 ± 0.003 6 and 1.061 8 ± 0.008 5, F = 0.073; with and without HER-2 The McAbs were 0.988 7 ± 0.003 7 and 1.061 8 ± 0.008 5, respectively, F = 0.075. Meanwhile, the expression of VEGF was not affected by the addition of paclitaxel, IGF-1R monoclonal antibody and HER-2 mAb. 3) The expression of VEGF in SKBR-3 breast cancer cells with and without VEGF monoclonal antibody was 1.005 7 ± 0.004 3,1.061 8 ± 0.008 5 respectively, the difference was statistically significant (F = 0.132, P = 0.04); however, There is no synergistic effect of anti-VEGF on the expression. CONCLUSIONS: The effect of different estrogen concentrations on the expression of VEGF in SKBR-3 breast cancer cells is obvious. Paclitaxel, IGF-1R monoclonal antibody and HER-2 monoclonal antibody have no effect on the expression of VEGF in SKBR-3 breast cancer cells and have no synergistic effect with estrogen. VEGF monoclonal antibody increased VEGF expression, but also with estrogen no synergistic effect.